FDA approval expected for expanded use of Zevalin

09/4/2009 | Reuters

Analysts are expecting the FDA to approve the use of Spectrum Pharmaceuticals' cancer drug Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The drug currently is approved as treatment for relapsed or refractory NHL. The FDA is set to hand down its decision on Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD